HCPCS Level II · Drugs administered other than oral method
J2779Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J2779
J2779 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg.
It was added to HCPCS effective 07/01/2022.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, susvimo 0.1 mg
- Date added
- 07/01/2022
- Action effective
- 07/01/2022
- BETOS
- O1E
Related J27xx codes
- J2700Injection, oxacillin sodium, up to 250 mg
- J2704Injection, propofol, 10 mg
- J2710Injection, neostigmine methylsulfate, up to 0.5 mg
- J2711Injection, neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg
- J2720Injection, protamine sulfate, per 10 mg
- J2724Injection, protein c concentrate, intravenous, human, 10 iu
- J2725Injection, protirelin, per 250 mcg
- J2730Injection, pralidoxime chloride, up to 1 gm
- J2760Injection, phentolamine mesylate, up to 5 mg
- J2765Injection, metoclopramide hcl, up to 10 mg
- J2770Injection, quinupristin/dalfopristin, 500 mg (150/350)
- J2777Injection, faricimab-svoa, 0.1 mg
Common questions about J2779
Is HCPCS J2779 still valid?
- Yes. J2779 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J2779?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.